Leadership
Abeona Therapeutics Awards Up to 5,100 Restricted Shares to Two New Non-Executive Employees
By News Desk ·
Key takeaways
- Abeona Therapeutics granted restricted stock awards covering up to 5,100 shares to two new non-executive employees on October 31, 2026.
- One-third of each employee's restricted shares vests yearly, with full vesting on the third anniversary of the grant date.
- Abeona appointed Syndax Pharmaceuticals CFO Keith A. Goldan to its board as Chairman of the Audit Committee in April 2026.
Abeona Therapeutics granted restricted stock awards covering up to 5,100 shares to two new non-executive employees on October 31, 2026, the company said in a GlobeNewswire announcement on November 2, 2026. The awards were approved under Nasdaq Listing Rule 5635(c)(4).
How the Abeona Inducement Awards Vest
The Compensation Committee of Abeona Therapeutics' board of directors approved the grants as a material inducement to employment for the two individuals hired by the company. One-third of the shares subject to each restricted stock award is scheduled to vest yearly on each anniversary of the grant date, so each employee's shares are scheduled to be fully vested on the third anniversary. Vesting is subject to each employee's continued employment with Abeona on the applicable vesting dates.
Abeona describes itself as a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Its ZEVASKYN (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. The company's cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production, and its development portfolio includes ABO-701 (PSMA-SIR-T), an engineered T-cell therapy targeting PSMA.
Abeona's Board and Financial Leadership Record
According to akta.pro company records, Abeona appointed Keith A. Goldan, chief financial officer of Syndax Pharmaceuticals, to its board of directors as Chairman of the Audit Committee in April 2026, adding public-company financial leadership to the board. The same records list Vishwas Seshadri as president and chief executive officer, Joseph Vazzano as chief financial officer, Vasanthavada Madhav as chief commercial officer and Brendan M. O'Malley as senior vice president and chief legal officer. The records give Abeona a headcount range of 101 to 250 employees.
James Russell's Push for Board Changes at Abeona
On October 23, 2026, James Russell, through his revocable trust, filed a Schedule 13D revealing a 6.1% stake in Abeona Therapeutics, TradingView reported. He cited governance concerns and urged the board to add independent directors and consider executive changes.
Abeona outlined its early commercial rollout of ZEVASKYN, an autologous cell sheet gene therapy for RDEB, at the Morgan Stanley Global Healthcare Conference, MarketBeat reported on September 22, 2026. Chief executive Vishwas Seshadri and chief commercial officer Madhav Vasanthavada presented at Morgan Stanley's 24th Annual Global Healthcare Conference on September 16, 2026, according to a Seeking Alpha transcript summary.